CONSOLIDATED FINANCIAL STATEMENTS AND REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

DECEMBER 31, 2024

	<u>Page</u>
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS	1-2
FINANCIAL STATEMENTS	
Consolidated Statements of Financial Position,	
December 31, 2024 And 2023	3
Consolidated Statements of Activities And Changes In Net Assets,	
Years Ended December 31, 2024 With Summarized Information For 2023	4
Consolidated Statement of Functional Expenses,	
Year Ended December 31, 2024	5
Consolidated Statement of Functional Expenses,	
Year Ended December 31, 2023	6
Consolidated Statements of Cash Flows,	
Years Ended December 31, 2024 And 2023	7
Notes To Consolidated Financial Statements	8-14



REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

Board of Directors HelpMeSee, Inc. New York, New York

Opinion

We have audited the accompanying consolidated financial statements of HelpMeSee, Inc. (the "Organization"), which comprise the consolidated statements of financial position as of December 31, 2024 and the related consolidated statement of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Organization as of December 31, 2024, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

Board of Directors HelpMeSee, Inc. New York, New York

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited the Organization's 2023 consolidated financial statements, and our report dated June 20, 2024, expressed an unmodified audit opinion on those audited financial statements. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2023 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Tait, Weller ! Bahen Lip

Philadelphia, Pennsylvania May 29, 2025

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

December 31, 2024 And 2023

	2024	<u>2023</u>
ASSETS		
ASSETS		
Cash and cash equivalents	\$ 9,184,559	\$ 7,627,257
Accounts receivable	259,052	138,394
Pledges receivable <i>(Note 2)</i>	5,950	6,050
Prepaid expenses and other assets	307,248	248,015
Inventory	733,799	495,551
Furniture, equipment and capital expenses, net (Note 3)	10,628,010	11,546,206
Right of use assets (Note 6)	319,358	443,506
Total assets	<u>\$21,437,976</u>	<u>\$20,504,979</u>

LIABILITIES AND NET ASSETS

LIABILITIES Accounts and accrued expenses payable Deferred revenue Operating lease liability <i>(Note 6)</i>	\$ 1,458,290 19,703 <u>341,840</u>	\$ 1,851,873 22,212 <u>478,825</u>
Total liabilities	1,819,833	2,352,910
NET ASSETS Without donor restrictions With donor restrictions <i>(Note 4)</i>	12,010,352 7,607,791	11,200,732
Total net assets	<u>19,618,143</u>	18,152,069
Total liabilities and net assets	<u>\$ 21,437,976</u>	<u>\$ 20,504,979</u>

CONSOLIDATED STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS

Year Ended December 31, 2024 With Summarized Information For 2023

	Without Donor	With Donor	ТО	TALS
	Restrictions	Restrictions	2024	2023
PUBLIC SUPPORT				
Individuals	\$ 443,081	\$ 35,118	\$ 478,199	\$ 378,393
Corporations	-	375,000	375,000	64,833
Foundations (<i>Note 5</i>)	16,442,641	690,000	17,132,641	17,187,676
Investment income	48,735	232,790	281,525 478,720	213,896 141,944
Training income Other income	478,720 165,204	-	165,204	21,984
Net assets released from restriction (Note 4)	676,454	(676,454)		
Total revenue and other support	18,254,835	656,454	18,911,289	18,008,726
EXPENSES				
Program services				
Training Cataract specialists and supporting				
practice readiness	13,743,721	-	13,743,721	12,246,072
Public awareness	809,848		809,848	926,516
Total program services	14,553,569		14,553,569	
Supporting services				
Management and general	1,150,154	-	1,150,154	1,261,139
Fundraising	1,677,325		1,677,325	2,706,254
Total supporting services	2,827,479		2,827,479	3,967,393
Total expenses	17,381,048		17,381,048	17,139,981
Surplus of revenue over expenses	873,787	656,454	1,530,241	868,745
OTHER CHANGES				
Foreign currency loss	(64,167)		(64,167)	(37,103)
Change in net assets	809,620	656,454	1,466,074	831,642
NET ASSETS				
Beginning of year	11,200,732	6,951,337	18,152,069	17,320,427
End of year	<u>\$12,010,352</u>	<u>\$7,607,791</u>	<u>\$19,618,143</u>	<u>\$18,152,069</u>

CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES

Year Ended December 31, 2024

	Training Cataract Specialists And Supporting <u>Practice Readiness</u>	Public <u>Awareness</u>	Total Program <u>Services</u>	Management And <u>General</u>	Fundraising	2024 Total <u>Expense</u>
Salaries	\$ 4,182,420	\$ 437,084	\$ 4,619,504	\$ 814,908	\$ 838,404	\$ 6,272,816
Benefits and related payroll expenses	682,274	71,301	753,575	132,935	136,768	1,023,278
Total salaries and related costs	4,864,694	508,385	5,373,079	947,843	975,172	7,296,094
Program grants/costs						
Surgeries and surgical kits	1,234	-	1,234	-	-	1,234
Simulator maintenance	833,034	1,155	834,189	-	-	834,189
Professional services	2,055,988	74,247	2,130,235	150,410	418,301	2,698,946
Printing and postage	11,752	513	12,265	661	2,849	15,775
Travel and meetings	526,432	93,474	619,906	8,049	22,179	650,134
Office expenses	384,454	1,752	386,206	10,294	3,888	400,388
Advertising and promotion	14,395	90,989	105,384	-	148,346	253,730
IT and web	279,785	35,596	315,381	7,727	83,647	406,755
Depreciation expense	4,290,584	-	4,290,584	-	-	4,290,584
Miscellaneous expense	481,369	3,737	485,106	25,170	22,943	533,219
Total expenses	<u>\$13,743,721</u>	<u>\$ 809,848</u>	<u>\$14,553,569</u>	<u>\$1,150,154</u>	<u>\$1,677,325</u>	<u>\$17,381,048</u>

CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES

Year Ended December 31, 2023

	Training Cataract Specialists And Supporting <u>Practice Readiness</u>	Public <u>Awareness</u>	Total Program <u>Services</u>	Management And General	Fundraising	2023 Total <u>Expense</u>
Salaries	\$ 3,691,943	\$277,554	\$ 3,969,497	\$ 612,663	\$ 998,315	\$ 5,580,475
Benefits and related payroll expenses	669,633	50,342	719,975	111,123	181,071	1,012,169
Total salaries and related costs	4,361,576	327,896	4,689,472	723,786	1,179,386	6,592,644
Program grants/costs						
Surgeries and surgical kits	6,156	-	6,156	-	-	6,156
Simulator maintenance	730,241	7,430	737,671	-	-	737,671
Professional services	2,286,404	199,670	2,486,074	449,065	1,211,167	4,146,306
Printing and postage	17,780	2,105	19,885	1,684	2,564	24,133
Travel and meetings	366,955	295,304	662,259	11,591	34,476	708,326
Office expenses	482,915	1,838	484,753	19,736	18,495	522,984
Advertising and promotion	218	40,187	40,405	-	181,227	221,632
IT and web	272,980	8,839	281,819	34,533	48,362	364,714
Depreciation expense	3,482,421	-	3,482,421	2,320	-	3,484,741
Miscellaneous expense	238,426	43,247	281,673	18,424	30,577	330,674
Total expenses	<u>\$12,246,072</u>	<u>\$ 926,516</u>	<u>\$13,172,588</u>	<u>\$1,261,139</u>	<u>\$2,706,254</u>	<u>\$17,139,981</u>

CONSOLIDATED STATEMENTS OF CASH FLOWS

Years Ended December 31, 2024 And 2023

	<u>2024</u>	<u>2023</u>
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ 1,466,074	\$ 831,642
Adjustments to reconcile change in net assets to Net cash provided by operating activities:		
Depreciation Amortization of right-of-use asset Operating lease liability payments	4,290,584 230,720 (243,557)	3,484,741 228,540 (232,041)
(Increase)/decrease in assets: Accounts receivable Pledges receivable Grants receivable Prepaid expenses and other assets Inventory	(120,658) 100 (59,233) (238,248)	855,375 100 55,269 (83,058) 25,033
Increase/(decrease) in liabilities: Accounts payable and accrued expenses Deferred revenue	(393,583) (2,509)	(359,547) <u>22,212</u>
Net cash provided by operating activities	4,929,690	4,828,266
CASH FLOWS FROM INVESTING ACTIVITIES Purchases of furniture, equipment and capital expenses Net cash used for investment activities	<u>(3,372,388)</u> (3,372,388)	<u>(5,561,153</u>) <u>(5,561,153</u>)
	. ,	
Net increase (decrease) in cash and cash equivalents	1,557,302	(732,887)
CASH Beginning of year	7,627,257	8,360,144
End of year	<u>\$ 9,184,559</u>	<u>\$ 7,627,257</u>
SUPPLEMENTAL DISCLOSURE	¢	¢ (70.01)
Right-of-use-asset in exchange for new financing liability	<u>\$</u>	<u>\$ 672,046</u>

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 And 2023

(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION AND PURPOSE

HelpMeSee, Inc., (the *"Organization"*) is a global campaign to eliminate blindness caused by untreated cataracts. Twenty million people living in the developing world are blind for two basic reasons:

- 1. They have no access to highly trained cataract specialists where they live. In many countries, there are as few as one ophthalmologist per one million people.
- 2. They are impoverished, earning just \$1 or \$2 per day when they are employed, so they cannot afford treatment even if it were available.

The centerpiece of the HelpMeSee strategy is to increase surgical access by training thousands of highly skilled cataract specialists to perform Manual Small Incision Cataract Surgery (MSICS). This operation can be quick, highly effective, and very low-cost procedure with results comparable to more technology dependent procedures practiced in the developed world. Nearly 50% of the patients with blindness from cataract surgeons perform two methods of cataract surgery, MSICS and Phacoemulsification (Phaco). Because both procedures are practiced regularly in these countries, there is a high demand for simulation-based training in Phaco as well as MSICS. As such, HMS is developing simulation modules to teach standard Phaco and management of complications for both MSICS and Phaco.

It is HelpMeSee's intention to train approximately 30,000 MSICS specialists to perform 60 million surgeries in 20 years. HelpMeSee's specific goals are:

- Train cataract specialists (with emphasis on training women) to perform a single standardized surgical procedure (MSICS) safely, cost-effectively, and without complications.
- Achieve the largest possible scale by utilizing highly standardized training methods and equipment, including very high fidelity virtual reality simulators, courseware, and methods adapted from commercial aviation pilot training.
- Conduct the training of residents living in the developing world who are willing and eager to serve the poor living in remote communities.
- Train those individuals, based upon HelpMeSee's judgement, who have a high probability of successfully completing the course of instruction.
- Continuously improve quality of MSICS care, through applied research, refinement of procedural steps, and pre-sterilized single use surgical kits.
- Continuously develop and improve training modules in ophthalmic surgical care including technology for providing training for phacoemulsification, complication management and suturing. Efforts are in place to develop modules for anterior and posterior vitrectomy, and management of posterior capsular tear..
- Achieve the best standards of quality of surgical care, infection control and patient safety.
- Mobilize financial, material and volunteer resources to achieve sustainable funding solutions for the elimination
 of blindness caused by cataracts worldwide through private and public partnerships on behalf of the poor at the
 lowest possible cost.
- Provide educational, technical, and financial support when necessary including loans to graduates so they may
 establish "best practice" business and surgical management systems specific to their practice locale in order to
 deliver high volume and high quality cataract surgeries, which are patient-centered. HelpMeSee aims to achieve
 this with the establishment of partnerships with other charitable organizations.
- Establish/utilize a web and cloud based electronic surgical report system for surgical quality assurance and monitoring and evaluation of outcomes for every graduate and patient.
- Develop proactive surgical eye-care policies with country governments and local insurance providers to include MSICS as essential surgery within the primary healthcare delivery.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

December 31, 2024 And 2023

HelpMeSee, based out of New Jersey, has controlled entities in the United States, China and India. New for-profit corporations have been organized in the United States, China and India; HMS Vision, Inc (U.S.A.), Beijing HMS Vision Technical Consulting Co. Ltd., and Help Me See India Private Limited Company, respectively, with the aim of achieving self-sustainability in pursuit of HelpMeSee's mission. Efforts are underway to phase out the existing entities in India.

BASIS OF PRESENTATION

The financial statements include the accounts of the Organization, HMS Vision Inc. (U.S.A.) and its controlled entities located in China and India.

The financial statements are presented in U.S. dollars. The financial records of these branch offices and controlled organizations are kept in local currencies. Assets, liabilities and net assets are translated at year-end rates of exchange and revenue and expenses are translated using the month end exchange rates supplied by an independent source. Significant intercompany transactions have been eliminated in the consolidation.

ACCOUNTING ESTIMATES

In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.

CONCENTRATION OF CREDIT RISK

The Organization occasionally maintains deposits in excess of federally insured limits. Accounting Standards Codification *("ASC")* 825, *"Financial Instruments"*, identifies these items as a concentration of credit risk requiring disclosure, regardless of the degree of risk. The risk is managed by monitoring the financial institutions in which deposits are made.

CASH AND CASH EQUIVALENTS

The Organization considers all highly liquid instruments purchased with a maturity of three months or less to be cash and cash equivalents.

INVENTORY

Inventory is carried at the lower of cost or market, using the first-in, first-out valuation method.

FIXED ASSETS AND CAPITAL EXPENSES

Fixed assets are recorded at cost. Equipment is capitalized, while maintenance and repairs are expensed when incurred. The Organization provides depreciation on furniture, fixtures and equipment by the straight-line method at rates calculated using the estimated useful lives of the respective depreciable assets, generally three to seven years. Capital expenses in connection with enhancements of existing equipment (simulators) are capitalized and depreciated. Capital expenses in connection with prototype equipment are expensed as incurred.

REVENUE RECOGNITION

Training income revenue is based on the premise that the Organization has a performance obligation to provide simulator training to individuals who complete the training program. As compensation for these services, the Organization is entitled to a training fee based on the services provided.

The Organization recognizes contributions when cash, securities or other assets; an unconditional promise to give; or a notification of a beneficial interest is received. Conditional promises to give – that is, those with a measurable performance or other barrier and right of return – are not recognized until the conditions on which they depend have been met.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

December 31, 2024 And 2023

Contributions and promises to give are considered available for general use unless specifically restricted by the donor. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. Gifts-in-kind are recorded at fair value on the date of receipt.

NET ASSETS

The Organization's net assets and revenues, expenses, gains and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets of the Organization and changes therein are classified and reported as follows:

Without donor restrictions – Net assets that are not subject to donor-imposed stipulations and that may be expendable for any purpose in performing the primary mission of the Organization. Net assets without donor restrictions consist of assets for general operations.

With donor restrictions – Net assets subject to donor-imposed restrictions that will be met either by actions of the Organization or the passage of time. Items that affect this net asset category are gifts for which donor-imposed restrictions have not been met in the year of receipt, including gifts and pledges. Expirations of restrictions of net assets with donor restrictions are reported as net assets released from restriction.

FUNCTIONAL ALLOCATION OF EXPENSES

The financial statements report certain categories of expenses that are attributable to more than one program or supporting function. These expenses require allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries, benefits, IT and Web and depreciation. These expenses are allocated based on analysis of time and effort and other factors determined by management.

INCOME TAXES

The Organization is exempt from Federal income taxes under Internal Revenue Code Section 501(c)(3) of the Internal Revenue Code and recognized as a public charity under Section 509(a)(1) of the Internal Revenue Code.

Management has reviewed the tax positions for the open tax years 2021 - 2023 or expected to be taken on the Organization's 2024 tax return and has concluded that there are no significant uncertain tax positions that would require recognition in the financial statements.

PRIOR YEAR INFORMATION

The financial statements include certain prior-year summarized comparative information in total, but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the Organization's audited financial statements for the year ended December 31, 2023, from which the summarized information was derived.

RECLASSIFICATIONS

Certain reclassifications were made to the 2023 financial statements to conform to the 2024 presentation.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

December 31, 2024 And 2023

(2) PLEDGES RECEIVABLE

Pledges receivable are due as follows at December 31, 2024 and 2023:

	<u>2024</u>	2025
Receivable in one year	\$4,950	\$4,050
Receivable in one to five years	1,000	2,000
Total pledges receivable	<u>\$ 5,950</u>	<u>\$6,050</u>

2024

2022

(3) FURNITURE, EQUIPMENT AND CAPITAL EXPENSES

At December 31, 2024 and 2023, furniture and equipment consists of the following:

	<u>2024</u>	<u>2023</u>
Office furniture	\$ 37,192	\$ 37,192
Office equipment	124,217	153,319
Leasehold improvements	330,655	339,344
Simulators	8,432,028	8,432,028
Simulator development	10,617,816	7,578,593
Courseware	4,576,259	4,255,583
Computers	160,353	148,076
	24,278,520	20,944,135
Less: accumulated depreciation and amortization	(13,650,510)	<u>(9,397,929</u>)
	<u>\$ 10,628,010</u>	<u>\$11,546,206</u>

Depreciation expense for the years ended December 31, 2024 and 2023 totaled \$4,290,584 and \$3,484,741, respectively.

The Organization continues to enhance its virtual reality simulator and courseware to train cataract specialist in Manual Small Incision Cataract Surgery (MSICS) and phacoemulsification (Phaco). The design calls to achieve a level of realism that is virtually indistinguishable from live surgery performed by an experienced surgeon. This will replace traditional MSICS training with simulator-based proficiency training rather than using it as an adjunct to live training. Additionally, the Phaco simulation-based proficiency training will flatten the learning curve and result in lower complication rates and lower ocular morbidity in live surgery. The Organization is applying the aviation FAA level D simulator standard both as a quality standard and as a template for developing the simulator. The various component technologies required for simulation that meets the Organizations goals are:

- Haptic
- Large incision, topological changes
- Tissue/tool collision
- Deformation
- Force calculation

Proficiency level of training of cataract surgeons is accomplished with Instructor Based Training (IBT), Computer Based Training (CBT) and Simulator Based Training (SBT) instructional curriculum and learning management systems. The Organization has successfully developed proof of concept models of the Eye Surgical Simulator for Cataract. Based on relative merits of the models and cost considerations the chosen concept will go into further development and production. A physics based model of the eye is developed with the support of highly experienced subject matter experts to ensure that the virtual reality technology is as effective for skill development as a surgeon would learn while operating on patients and with an added advantage of zero patient risk.

In 2024, the Organization continued development of virtual reality simulation and courseware to train cataract specialists in Phaco. These costs are being capitalized.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

December 31, 2024 And 2023

(4) NET ASSETS

Net assets with donor restrictions are available for the following purposes at December 31, 2024 and 2023:

	<u>2024</u>	<u>2023</u>
Subject to expenditure for a special purpose:		
Cataract surgeries	\$ 5,721,485	\$ 5,495,403
Patient database	306,839	261,923
Training	1,579,467	1,194,011
Total	<u>\$7,607,791</u>	<u>\$6,951,337</u>

Net assets of \$4,378,888 and \$4,822,552 at December 31, 2024 and December 31, 2023, respectively, relates to a previous award to the Organization of restricted contributions from the transfer of a the bankruptcy of a nonprofit organization administered by the New York Attorney General's office.

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purpose as follows for the year ended December 31, 2024:

	<u>2024</u>
Litigation Award Funds:	
Training	\$633,726
Patient database	42,728
Total	<u>\$676,454</u>

(5) CONTRIBUTIONS

For the year ended December 31, 2024, the Organization received contributions from two foundations in the amount of \$16,945,000, which represents 90% of the Organization's total revenue. For the year ended December 31, 2023, the Organization received contributions from one foundation in the amount of \$16,932,000, which represented 94% of the Organization's total revenue.

(6) LEASES

The Organization has agreements to lease office space under several leases, with an initial term greater than 12 months. The Organization determines whether an agreement is or contains a lease at lease inception. Right-of-use assets represent the Organization's right to use an underlying asset for the lease term and lease liabilities represent the Organization's obligation to make lease payments arising from the lease, measured at an amount equal to the present value of the minimum lease payments over the remaining expected term of the lease. Rent is being expended on a straight - line basis over the term of the leases. Amortization expense and interest expense related to the Organization's finance leases are included in office expenses, on the statement of functional expenses.

In determination of the lease term, the Organization considers the likelihood of lease renewal options and lease termination provisions.

The discount rate for a lease is derived from the rate implicit in the lease whenever readily determinable or the Organization's incremental borrowing rate.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

December 31, 2024 And 2023

The following quantitative data related to the Organization's operating leases for the years ended December 31, 2024 and 2023 is as follows:

	<u>2024</u>	<u>2023</u>
Operating Lease Amounts:		
Right-of-use assets	\$319,358	\$443,506
Lease liabilities	341,840	478,825
Other Information:		
Operating outgoing cash flows for operating leases	\$250,434	\$240,139
Weighted-average remaining lease term	1.43 Years	2.08 years
Weighted average discount rate	1.32%	1.34%

Lease cost information for the years ended December 31, 2024 and 2023 is as follows:

	<u>2024</u>	<u>2023</u>
Operating lease cost	<u>\$236,784</u>	<u>\$236,638</u>

The Organization has leases for office space, which expire through May 2026, for its New York, New Jersey, China and India offices.

Future lease payments at December 31, 2024 are as follows:

Fiscal Year	Amount
2025	\$253,092
2026	<u>87,914</u>
Total undiscounted cash flows	341,006
Less: present value adjustment	<u>834</u>
Lease liability	<u>\$341,840</u>

(7) FINANCIAL ASSETS AND LIQUIDITY RESOURCES

The Organization strives to maintain liquid financial assets to be available as its general expenditures, liabilities and other obligations become due. Financial assets in excess of daily cash requirements are invested in an interest-bearing cash account. As part of the Organization's liquidity management, it has a practice to structure its financial assets to be available as its general expenditures, liabilities and other obligations come due.

The following table reflects the Organization's financial assets as of December 31, 2024 and 2023, reduced by amounts that are not available to meet general expenditures within one year of the statement of financial position date because of contracted restrictions. Amounts not available to meet general expenditures within one year may include net assets with donor restrictions.

Financial Assets	<u>2024</u>	<u>2023</u>
Cash and cash equivalents Accounts receivable Pledges receivable	\$ 9,184,559 259,052 <u>5,950</u>	\$ 7,627,257 138,394 <u>6,050</u>
Less: Restricted net assets not to be expended within one year	9,449,561 <u>(7,451,099</u>)	7,771,701 (6,221,567)
Total financial assets available within one year	<u>\$ 1,998,462</u>	<u>\$ 1,550,134</u>

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

December 31, 2024 And 2023

(8) SUBSEQUENT EVENTS

Subsequent events after the balance sheet date through the date that the financial statements were available for issuance, May 29, 2025 have been evaluated in the preparation of the financial statements.